An Improved Isoform-Selective Assay for Sphingosine Kinase 1 Activity

2017 ◽  
pp. 9-20
Author(s):  
Melissa R. Pitman ◽  
Lorena T. Davies ◽  
Stuart M. Pitson
Keyword(s):  
Sphingosine Kinase ◽  
Sphingosine Kinase 1

Sphingosine kinase 1 is a relevant molecular target in gastric cancer

2011 ◽  
Vol 22 (3) ◽  
pp. 245-252 ◽  
Author(s):  
Thorsten Fuereder ◽  
Doris Hoeflmayer ◽  
Agnes Jaeger-Lansky ◽  
Doris Rasin-Streden ◽  
Sabine Strommer ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Sphingosine Kinase ◽  
Molecular Target ◽  
Sphingosine Kinase 1

scholarly journals The localization and activity of sphingosine kinase 1 are coordinately regulated with actin cytoskeletal dynamics in macrophages. VOLUME 282 (2007) PAGES 23147-23162

2008 ◽  
Vol 283 (9) ◽  
pp. 5972
Author(s):  
David J. Kusner ◽  
Christopher R. Thompson ◽  
Natalie A. Melrose ◽  
Stuart M. Pitson ◽  
Lina M. Obeid ◽  
...  
Keyword(s):  
Sphingosine Kinase ◽  
Sphingosine Kinase 1 ◽  
Cytoskeletal Dynamics ◽  
Actin Cytoskeletal Dynamics

scholarly journals Silencing of Sphingosine kinase 1 Affects Maturation Pathways in Mouse Neonatal Cardiomyocytes

2021 ◽  
Vol 22 (7) ◽  
pp. 3616
Author(s):  
Ewelina Jozefczuk ◽  
Piotr Szczepaniak ◽  
Tomasz Jan Guzik ◽  
Mateusz Siedlinski
Keyword(s):  
Cardiac Development ◽  
Glycogen Synthase ◽  
Sphingosine Kinase ◽  
Negative Control ◽  
Neonatal Mouse ◽  
Sphingosine Kinase 1 ◽  
Postnatal Maturation ◽  
Neonatal Cardiomyocytes ◽  
Pathological Cardiac Hypertrophy

Sphingosine kinase-1 (Sphk1) and its product, sphingosine-1-phosphate (S1P) are important regulators of cardiac growth and function. Numerous studies have reported that Sphk1/S1P signaling is essential for embryonic cardiac development and promotes pathological cardiac hypertrophy in adulthood. However, no studies have addressed the role of Sphk1 in postnatal cardiomyocyte (CM) development so far. The present study aimed to assess the molecular mechanism(s) by which Sphk1 silencing might influence CMs development and hypertrophy in vitro. Neonatal mouse CMs were transfected with siRNA against Sphk1 or negative control, and subsequently treated with 1 µM angiotensin II (AngII) or a control buffer for 24 h. The results of RNASeq analysis revealed that diminished expression of Sphk1 significantly accelerated neonatal CM maturation by inhibiting cell proliferation and inducing developmental pathways in the stress (AngII-induced) conditions. Importantly, similar effects were observed in the control conditions. Enhanced maturation of Sphk1-lacking CMs was further confirmed by the upregulation of the physiological hypertrophy-related signaling pathway involving Akt and downstream glycogen synthase kinase 3 beta (Gsk3β) downregulation. In summary, we demonstrated that the Sphk1 silencing in neonatal mouse CMs facilitated their postnatal maturation in both physiological and stress conditions.

Investigation of sphingosine kinase 1 inhibitory potential of cinchonine and colcemid targeting anticancer therapy

2021 ◽  
pp. 1-13 ◽  
Author(s):  
Sonam Roy ◽  
Shama Khan ◽  
Deeba Shamim Jairajpuri ◽  
Afzal Hussain ◽  
Mohamed F. Alajmi ◽  
...  
Keyword(s):  
Sphingosine Kinase ◽  
Anticancer Therapy ◽  
Sphingosine Kinase 1 ◽  
Inhibitory Potential

scholarly journals Reduced sphingosine kinase 1 activity in dengue virus type-2 infected cells can be mediated by the 3′ untranslated region of dengue virus type-2 RNA

2013 ◽  
Vol 94 (11) ◽  
pp. 2437-2448 ◽  
Author(s):  
J. M. Carr ◽  
T. Kua ◽  
J. N. Clarke ◽  
J. K Calvert ◽  
J. R. Zebol ◽  
...  
Keyword(s):  
Cell Death ◽  
Dengue Virus ◽  
Virus Type ◽  
Elongation Factor ◽  
Sphingosine Kinase ◽  
Sphingosine Kinase 1 ◽  
Diarrhea Virus ◽  
Infected Cells ◽  
Dengue Virus Type 2

Sphingosine kinase 1 (SphK1) is a lipid kinase with important roles including regulation of cell survival. We have previously shown reduced SphK1 activity in cells with an established dengue virus type-2 (DENV-2) infection. In this study, we examined the effect of alterations in SphK1 activity on DENV-2 replication and cell death and determined the mechanisms of the reduction in SphK1 activity. Chemical inhibition or overexpression of SphK1 after established DENV-2 infection had no effect on infectious DENV-2 production, although inhibition of SphK1 resulted in enhanced DENV-2-induced cell death. Reduced SphK1 activity was observed in multiple cell types, regardless of the ability of DENV-2 infection to be cytopathic, and was mediated by a post-translational mechanism. Unlike bovine viral diarrhea virus, where SphK1 activity is decreased by the NS3 protein, SphK1 activity was not affected by DENV-2 NS3 but, instead, was reduced by expression of the terminal 396 bases of the 3′ UTR of DENV-2 RNA. We have previously shown that eukaryotic elongation factor 1A (eEF1A) is a direct activator of SphK1 and here DENV-2 RNA co-localized and co-precipitated with eEF1A from infected cells. We propose that the reduction in SphK1 activity late in DENV-2-infected cells is a consequence of DENV-2 out-competing SphK1 for eEF1A binding and hijacking cellular eEF1A for its own replication strategy, rather than a specific host or virus-induced change in SphK1 to modulate viral replication. Nonetheless, reduced SphK1 activity may have important consequences for survival or death of the infected cell.

Design, Synthesis and Analysis of Novel Sphingosine Kinase-1 Inhibitors to Improve Oral Bioavailability

2021 ◽  
pp. 128329
Author(s):  
Kendarius J. Butler ◽  
Angel A. Castro ◽  
Tiffany S. Dwyer ◽  
Louise M. Hardwick ◽  
Melody C. Iacino ◽  
...  
Keyword(s):  
Oral Bioavailability ◽  
Sphingosine Kinase ◽  
Sphingosine Kinase 1 ◽  
Design Synthesis
Sign in / Sign up

Export Citation Format

Share Document